Immitra Bio

Immitra BioImmitra Bio
Immitra Bio

Immitra Bio

Scalable, one-time curative in-vivo gene editing therapies.

Website
2024ActiveZürich, Switzerland
Rate
Advertise here

About

Immitra Bio is developing a scalable, in-vivo gene editing platform designed to offer a single, off-the-shelf injection to cure rare genetic diseases. Their mission is to provide accessible, curative genetic medicine for the 400 million people worldwide affected by these conditions, addressing the limitations of current ex-vivo therapies.
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Immitra Bio do?

Immitra Bio is developing a scalable, in-vivo gene editing platform designed to offer a single, off-the-shelf injection to cure rare genetic diseases. Their mission is to provide accessible, curative genetic medicine for the 400 million people worldwide affected by these conditions, addressing the limitations of current ex-vivo therapies. (formerly [].)

How much funding has Immitra Bio raised?

Immitra Bio has raised a total of $3M in funding. The most recent round on record is Pre-Seed.

Where is Immitra Bio headquartered?

Immitra Bio is headquartered in Zürich, Switzerland.

When was Immitra Bio founded?

Immitra Bio was founded in 2024.

What industry does Immitra Bio operate in?

Immitra Bio operates in Biotechnology, Gene Therapy, Genetics, Healthcare, Pharmaceuticals, Biotech.

What is Immitra Bio's revenue?

StartupHub estimates Immitra Bio's annual revenue at $315K (range $85K to $946K, 36% confidence), based on comparable companies in the sector.

What is Immitra Bio's valuation?

StartupHub estimates Immitra Bio's effective valuation at $9.7M (range $6.5M to $15.5M, 25% confidence), based on comparable companies in the sector.